Drugs / LC542019
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06333977 | Mar 2022 → Dec 2023 | type 2 diabetes mellitus | LG Chem | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-01-19 | LG Life Sciences | Regulatory LG Chem Begins Phase 1 Clinical Trials for New Diabetes Drug for Improving Insulin Resistance lgchem.com ↗
LG Chem announced on the 19th that it received approval for clinical phase 1 studies (investigational new drug; IND) for ‘LC542019’, which is a new drug candidate material for treating type 2 diabetes that can improve insulin resistance from the US FDA. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-01-19 | LG Life Sciences | LG Chem Begins Phase 1 Clinical Trials for New Diabetes Drug for Improving Insulin Resistance lgchem.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LC542019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06333977 ↗ |
| Route | Oral | “oral dose, once daily” NCT06333977 ↗ |